Exousia Bio (LMMY) Total Non-Current Liabilities (2022 - 2024)

Exousia Bio has disclosed Total Non-Current Liabilities across 3 years of filings, most recently posting $69595.0 for Q3 2024.

• Total Non-Current Liabilities for Q3 2024 came in at $69595.0, up 8.85% year-over-year; the trailing twelve-month figure through Aug 2024 was $69595.0 (up 8.85% YoY), and the FY2024 annual result was $68179.0, up 9.05% from the prior year.
• Total Non-Current Liabilities came in at $69595.0 for Q3 2024 at Exousia Bio, up from $68179.0 in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $69595.0 in Q3 2024 to a low of $54433.0 in Q2 2022.
• The 3-year median for Total Non-Current Liabilities is $64643.0 (2023), against an average of $63986.4.
• Across the five-year window, Total Non-Current Liabilities increased 14.86% in 2023 and increased 8.85% in 2024, its largest moves.
• Exousia Bio's Total Non-Current Liabilities stood at $54433.0 in 2022, then climbed by 20.06% to $65350.0 in 2023, then advanced by 6.5% to $69595.0 in 2024.
• The last three Total Non-Current Liabilities figures came in at $69595.0 (Q3 2024), $68179.0 (Q2 2024), and $66765.0 (Q1 2024), per Business Quant data.